A detailed history of Taylor Wealth Management Partners transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Taylor Wealth Management Partners holds 24,190 shares of ALNY stock, worth $5.7 Million. This represents 2.0% of its overall portfolio holdings.

Number of Shares
24,190
Previous 26,056 7.16%
Holding current value
$5.7 Million
Previous $4.26 Million 17.09%
% of portfolio
2.0%
Previous 1.72%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$120.42 - $169.29 $224,703 - $315,895
-1,866 Reduced 7.16%
24,190 $3.53 Million
Q1 2022

May 11, 2022

SELL
$127.18 - $173.91 $136,972 - $187,301
-1,077 Reduced 3.97%
26,056 $4.26 Million
Q4 2021

Jan 28, 2022

SELL
$159.56 - $209.29 $111,053 - $145,665
-696 Reduced 2.5%
27,133 $4.6 Million
Q3 2021

Oct 26, 2021

SELL
$169.75 - $207.73 $120,692 - $147,696
-711 Reduced 2.49%
27,829 $5.25 Million
Q2 2021

Aug 11, 2021

SELL
$128.63 - $176.89 $138,019 - $189,802
-1,073 Reduced 3.62%
28,540 $4.84 Million
Q1 2021

Apr 21, 2021

SELL
$126.83 - $175.69 $129,493 - $179,379
-1,021 Reduced 3.33%
29,613 $4.18 Million
Q4 2020

Feb 02, 2021

BUY
$122.97 - $147.0 $737 - $882
6 Added 0.02%
30,634 $3.98 Million
Q3 2020

Oct 14, 2020

BUY
$121.19 - $165.49 $90,165 - $123,124
744 Added 2.49%
30,628 $4.46 Million
Q2 2020

Jul 27, 2020

SELL
$104.21 - $156.44 $399,749 - $600,103
-3,836 Reduced 11.38%
29,884 $4.43 Million
Q1 2020

May 04, 2020

BUY
$93.12 - $133.99 $3.14 Million - $4.52 Million
33,720 New
33,720 $3.67 Million
Q1 2019

May 14, 2019

SELL
$72.76 - $93.45 $5,820 - $7,476
-80 Closed
0 $0
Q4 2017

Feb 01, 2018

SELL
$114.49 - $139.98 $5,724 - $6,998
-50 Reduced 38.46%
80 $10,000
Q3 2017

Oct 13, 2017

BUY
$72.53 - $118.27 $9,428 - $15,375
130
130 $15,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Taylor Wealth Management Partners Portfolio

Follow Taylor Wealth Management Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Taylor Wealth Management Partners, based on Form 13F filings with the SEC.

News

Stay updated on Taylor Wealth Management Partners with notifications on news.